Biogen Inc. (BIIB) |
|
257.01 -0.82 (-0.32%)
|
09-29 16:00 |
|
Open: |
258.53 |
Pre. Close: |
257.83 |
|
High:
|
259.23 |
Low:
|
255.25 |
|
Volume:
|
887,332 |
Market Cap:
|
37,221(M) |
|
|
|
Technical analysis |
as of: 2023-09-29 4:26:10 PM |
|
Short-term rate:
|
  |
| Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 307.62 One year: 315.94 |
| Support: |
Support1: 251.85 Support2: 209.53 |
| Resistance: |
Resistance1: 263.37 Resistance2: 270.5 |
| Pivot: |
257.12 |
| Moving Average: |
MA(5): 257.08 MA(20): 258.72
MA(100): 279.62 MA(250): 281.06 |
| MACD: |
MACD(12,26): -2.5  Signal(9): -2.9 |
| Stochastic oscillator: |
%K(14,3): 51.1 %D(3): 45.5 |
| RSI: |
RSI(14): 42.4 |
| 52-week: |
High: 319.76 Low: 250.3 |
| Average Vol(K): |
3-Month: 1,013 (K) 10-Days: 771 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BIIB ] has closed above bottom band by 48.4%. Bollinger Bands are 63.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
259.83 - 261.11 |
261.11 - 262.15 |
|
Low:
|
251.68 - 253.43 |
253.43 - 254.86 |
|
Close:
|
254.56 - 257.21 |
257.21 - 259.36 |
|
Company Description |
|
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts. |
Headline News |
Fri, 29 Sep 2023
FDA Approves Biogen's TOFIDENCE™ (tocilizumab-bavi), a ... - Biogen
Fri, 29 Sep 2023
Biogen Inc. (NASDAQ:BIIB) Shares Acquired by Uncommon Cents ... - MarketBeat
Thu, 28 Sep 2023
First Week of November 17th Options Trading For Biogen (BIIB) - Nasdaq
Tue, 26 Sep 2023
Biogen Inc. stock outperforms market on strong trading day - MarketWatch
Tue, 26 Sep 2023
Biogen Completes Acquisition of Reata Pharmaceuticals | Biogen - Biogen
Mon, 25 Sep 2023
Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should ... - Nasdaq
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—General |
| Shares Out. |
145 (M) |
| Shares Float |
144 (M) |
|
% Held by Insiders
|
0.6 (%) |
|
% Held by Institutions
|
90.8 (%) |
|
Shares Short
|
3,140 (K) |
|
Shares Short P.Month
|
3,420 (K) |
Stock Financials |
|
EPS
|
18.22 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
99.91 |
|
Profit Margin (%)
|
26.7 |
|
Operating Margin (%)
|
26.2 |
|
Return on Assets (ttm)
|
6.5 |
|
Return on Equity (ttm)
|
20.2 |
|
Qtrly Rev. Growth
|
-5.1 |
|
Gross Profit (p.s.)
|
54.55 |
|
Sales Per Share
|
68.84 |
|
EBITDA (p.s.)
|
21.33 |
|
Qtrly Earnings Growth
|
-43.8 |
|
Operating Cash Flow
|
1,430 (M) |
|
Levered Free Cash Flow
|
1,710 (M) |
Stock Valuations |
|
PE Ratio
|
14.09 |
|
PEG Ratio
|
33.5 |
|
Price to Book value
|
2.57 |
|
Price to Sales
|
3.73 |
|
Price to Cash Flow
|
26.02 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
